It is important to note that oncogenic activity of HIF2α has only been clearly demonstrated in a limited number of tumor types, most notably in clear cell renal cell carcinoma (ccRCC) and paragangliomas (PPGL). This evidence concerns the gene EPAS1 and clear cell renal carcinoma.